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expression and synthesis of NF-κB inhibitors, IκBα and I-κB-β.
(4) DTF downregulates IL-1β-induced IκB kinase (IKK) activation
in cells treated with DTF/rest for 4/20, 8/16, 12/12, and 16/8.
Conclusions: This is the ﬁrst study to demonstrate persistent
effects of biomechanical signals in the surrounding proinﬂamma-
tory environment. Furthermore, biomechanical signals suppress
NF-kB signaling cascade. These signals act in two ways: (i) in-
hibit mRNA expression and synthesis of NF-κB, I-κBα and I-κBβ,
and (ii) downregulate IKKb activation and thus I-κB degradation.
The studies show the necessity of using adequate time intervals
of physical therapies for the optimal management of arthritic
joints.
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Purpose: Direct or indirect injuries to articular cartilage predis-
pose to osteoarthritis. We have previously shown that injury to
cartilage such as simple dissection causes the release of FGF-2
from a pericellular pool and activation of inﬂammatory signalling
pathways such as the mitogen activated protein kinases and
NFκB. Following such injury, the TGF β family member activin
A is synthesised by human articular cartilage. We investigated
a) how injury regulates the production of activin A by articular
cartilage and b) whether this molecule has an important function
in cartilage. Because TGF β has anti-inﬂammatory actions, the
effect of activin A on IL-1-induced breakdown of the proteoglycan
aggrecan in cartilage was assessed.
Methods: Activin A production was measured by ELISA of
porcine or human cartilage explant culture medium. mRNA in-
duction in cartilage explants or primary chondrocyte monolayers
was by RT-PCR for genes of interest. The effect of exogenous
activin A on IL-1 induced cleavage of aggrecan was determined
by western blotting medium from human cartilage explant culture
for the aggrecan cleavage neoepitope ARGSV.
Results: Activin A mRNA and protein were induced by sim-
ple dissection of human or porcine cartilage from the articular
surface. Its production was due to an active cellular process.
Activin A mRNA in cartilage explants was induced by FGF-2.
Activin A production following injury was reduced by 80% by the
FGF receptor inhibitor PD173074 and 70% by the IKK inhibitor
BMS345541. FGF appeared to induce activin A production via
ERK and src family kinases. Low concentrations of exogenous
activin A suppressed the IL-1 induced aggrecanase-mediated
cleavage of aggrecan in human articular cartilage. Osteoarthritic
cartilage was noted to produce signiﬁcantly more activin A than
normal cartilage.
Conclusions:Activin A is produced by chondrocytes in response
to injury of articular cartilage in an FGF and NFκB-dependent
manner. This molecule appears to be anti-catabolic for carti-
Abstract 160 – Table 1
Day 5 Day 9 Day 13
GAGs (µg)/DNA (µg) GAGs (µg)/DNA (µg) GAGs (µg)/DNA (µg)
(n) (n) (n)
Non-Obese Group (BMI < 30 kg/m2) 31.8 (3) 53.3 (6) 34.9 (2)
Obese Group (BMI > 30 kg/m2) 140.6 (6) 205.6 (6) 323.8 (3)
lage by preventing aggrecan breakdown, and its production is
enhanced in osteoarthritic tissue. Activin A may therefore be an
endogenous chondroprotective cytokine, whose actions might be
exploited therapeutically.
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Purpose: Osteoarthritis (OA) is the most common form of arthri-
tis in the United States and has been linked to obesity. It is
hypothesized that obesity, deﬁned as a body mass index (BMI)
over 30 kg/m2, increases the incidence of OA through increased
joint pressure and disruption of normal metabolism. Studies have
identiﬁed factors in obese patients that may function as regula-
tors of chondrocyte metabolism. However, metabolic changes
resulting from obesity that may precede OA have not been thor-
oughly investigated. The purpose of this study was to identify
the relationship between chondrocyte metabolism and BMI in
osteoarthritic tissue.
Methods: Grade 0 or 1 cartilage was removed from the me-
dial and/or lateral femoral condyles after total knee arthroplasty
and was digested in collagenase. The chondrocytes were then
resuspended in alginate beads at 2x106 cells/mL. The beads
were equilibrated in media containing 10% fetal bovine serum
for 7 days (37°C) and then separated into wells (8 beads/well)
with 1 mL media. Media was replaced every 48 hours. At day
5, 9, and 13, beads were dissolved in 55 mM sodium citrate
and centrifuged into their cell matrix and alginate portions. Gly-
cosaminoglycan (GAG) content was measured in the cell pellet,
alginate, and saved media using the dimethylmethylene blue
(DMMB) assay. The DMMB results were normalized to DNA con-
tent. To assess differences in GAG content between obese and
non-obese group, a Wilcoxon rank sum test was used. P < 0.05
was used as the criterion for signiﬁcance. All procedures were
approved by the University of Wisconsin - Madison, Institutional
Review Board.
Results: At day 5, the average normalized GAGs from the obese
group (BMI >30 kg/m2) was >4-fold higher than the average
normalized GAGs in the non-obese group (BMI <30 kg/m2).
Table 1 displays the normalized GAG averages from the 3 study
days.
Fig. 1 shows a signiﬁcant and linear relationship between BMI
and normalized GAGs at day 9 (p=0.0003).
The 4-fold difference in normalized GAGs between obese
and non-obese groups continued at day 9 with signiﬁcance
(p=0.0087) and widened at day 13, without signiﬁcance. Fig. 2
displays the day 9 averages of normalized GAG content from the
obese and non-obese groups.
Some osteoarthritic knees had less tissue quality, therefore GAG
testing was limited to earlier study days resulting in variable
sample numbers for each study day.
